rs992969 — IL33

IL33 — The Alarmin Switch of Type-2 Immunity

Every time your airways encounter an allergen, virus, or airborne irritant, epithelial cells lining the bronchi release a distress signal called IL-33 (interleukin-33)¹¹ IL-33 (interleukin-33)
An alarmin cytokine stored in epithelial cell nuclei and released upon tissue damage; it binds the ST2 receptor on mast cells, ILC2s, and eosinophils to initiate type-2 inflammation — the biological basis of allergic asthma, hay fever, and eczema. The rs992969 A allele, located roughly 5 kilobases upstream of the IL33 gene on chromosome 9, increases IL33 mRNA expression in bronchial epithelium, amplifying this signal. Across three atopic diseases — asthma, hay fever, and eczema — the A allele consistently raises risk, making it one of the most clinically meaningful shared regulatory variants in the atopy genome.

The Mechanism

rs992969 is an intergenic regulatory variant in the region between GTF3AP1 and IL33 on chromosome 9q24.2 (GRCh38 chr9:6,209,697). It does not alter any protein directly; instead, it lies within a regulatory element²² regulatory element
A DNA sequence that controls when and how much a nearby gene is transcribed, analogous to a volume knob for gene expression that controls IL33 transcription in airway epithelial and mast cells. Carriers of the A allele produce higher IL33 mRNA in bronchial tissue. This elevated expression translates directly to more IL-33 protein release upon epithelial damage.

The downstream cascade is well characterised: IL-33 binds the ST2 receptor³³ ST2 receptor
ST2 (encoded by IL1RL1) is the cell-surface receptor for IL-33; engagement activates MyD88/NF-κB signalling and drives gene expression in mast cells, ILC2s, and eosinophils on mast cells, group-2 innate lymphoid cells (ILC2s), eosinophils, and Th2 helper cells. The resulting cytokine cascade — IL-4, IL-5, IL-13 — drives Th2 polarisation⁴⁴ Th2 polarisation
The differentiation of naive T-helper cells toward a Th2 phenotype characterised by production of IL-4, IL-5, and IL-13, which mediate allergy, eosinophil recruitment, and IgE class switching in B cells, mast cell degranulation, eosinophil recruitment, and IgE class switching — the full machinery of allergic inflammation. A allele carriers therefore have a constitutively louder starting signal for this entire cascade after epithelial injury.

The Evidence

The IL33 locus was firmly established as a shared atopic disease gene in the landmark study by Ferreira et al. 2017⁵⁵ Ferreira et al. 2017
Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. Nature Genetics 2017; 360,838 participants, which meta-analysed 360,838 participants across genome-wide association studies of asthma, hay fever, and eczema. The IL33 locus — tagged by rs992969 and nearby variants — emerged as one of the top shared risk signals across all three conditions, with odds ratios in the range of 1.12–1.15 per A allele. The study demonstrated that most IL33-locus variation acts through the shared atopic biology rather than through disease-specific mechanisms, explaining why the A allele raises risk simultaneously for all three conditions.

For asthma specifically, the A allele shows stronger effects on childhood-onset than adult-onset disease. Pividori et al. 2019⁶⁶ Pividori et al. 2019
Shared and distinct genetic risk factors for childhood-onset and adult-onset asthma: genome-wide and transcriptome-wide studies. Lancet Respiratory Medicine 2019; 37,846 asthma cases found OR 1.25 (95% CI 1.21–1.29) for childhood-onset asthma versus OR 1.10 (95% CI 1.08–1.13) for adult-onset asthma — a 2.5-fold larger effect during the developmental period when the atopic immune phenotype is being established.

The eosinophil data provide the clearest window into mechanism. A cross-population atlas of 628,000 participants⁷⁷ cross-population atlas of 628,000 participants
Sakaue et al., Nature Genetics 2021; 220 phenotypes across BioBank Japan, UK Biobank, and FinnGen found rs992969 associated with eosinophil count at p=2×10⁻²¹³ — one of the most statistically robust associations in human genetics. Notably, the direction is inverse: the A risk allele associates with lower eosinophil counts (β=−0.062 SD). This is consistent with chronic IL-33-driven eosinophil degranulation and tissue trafficking rather than blood accumulation — a hallmark of active allergic disease.

The biological pathway is therapeutically validated. Itepekimab (REGN3500/SAR440340), a monoclonal antibody targeting IL-33 directly, demonstrated in a Phase 2 randomised controlled trial (Wechsler et al. 2021)⁸⁸ (Wechsler et al. 2021)
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. NEJM 2021; 296 patients a 54% reduction in asthma-control-loss events compared to placebo (OR 0.42, P=0.02). This pharmacological blockade of the same cytokine whose overexpression is driven by the A allele constitutes direct therapeutic validation of the mechanism.

Practical Actions

A allele carriers with a personal or family history of atopic disease face a genetically amplified IL-33 signalling baseline. Two complementary strategies are supported by evidence:

Vitamin D directly suppresses IL33 gene expression. Observational and mechanistic studies show that 1,25-dihydroxyvitamin D3 (the active form) reduces IL-33 transcription in bronchial epithelial cells, providing a tractable genomic lever for A allele carriers whose IL33 regulatory element is already pushed toward higher expression.

Omega-3 fatty acids (EPA/DHA) reduce systemic Th2 polarisation and ILC2 activation, working downstream of IL-33 release to dampen the cellular response even if IL-33 output remains elevated.

For AA homozygotes (both alleles driving elevated expression) with confirmed asthma or severe allergic disease, IL-33-targeting biologics (itepekimab) are pharmacogenomically relevant — their mechanism of action is precisely matched to this genotype's biological dysfunction.

Interactions

The most clinically important interaction is with the IL33 loss-of-function variant rs146597587. This rare splice-acceptor variant (C allele, ~0.4% in Europeans) produces a truncated, ST2-blind IL-33 protein that halves asthma risk. A carrier of both the common A risk allele at rs992969 and the rare C protective allele at rs146597587 has partially offsetting genetic influences on IL-33 output — the regulatory upregulation from one allele meeting the functional impairment from the other.

The parallel alarmin pathway mediated by TSLP (thymic stromal lymphopoietin, regulated by rs1837253) independently activates ILC2s and eosinophils. High-TSLP genotype combined with the A risk allele at rs992969 represents convergent activation of two non-redundant ILC2-activating pathways, a combination expected to produce more severe atopic disease than either variant alone — though this specific gene-gene interaction has not been formally modelled in published literature.